Insurance companies are increasingly restricting coverage for GLP-1 medications, impacting patient access and affordability.

Results from a Phase II trial (NCT06640972) showed that patients treated with RDX-002 experienced significant reductions in ...

Research carried out over the past year has shown a link between using GLP-1 medication for weight loss and a dangerous eye condition that results in sudden vision loss ...